Evoke, formally known as 888 holdings, expects its full-year 2024 adjusted earnings before interest, taxes, depreciation, and amortization to be at the high end of the previously guided range of 300 ...
Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...